Skip to main content
. 2024 Aug 20;16(8):e67307. doi: 10.7759/cureus.67307

Figure 2. Kaplan–Meier estimates of overall survival.

Figure 2

Kaplan–Meier estimates of overall survival (OS) for patients treated with ABCP therapy as the primary cytotoxic regimen following EGFR-TKIs in patients diagnosed with EGFR-positive non-squamous NSCLC. The median OS was 23.6 months (95% CI: 14.5 months - not reached).

Abbreviations: ABCP, atezolizumab, bevacizumab, carboplatin, and paclitaxel; CI, confidence interval; EGFR, epithelial growth factor receptor; OS, overall survival; TKI, tyrosine kinase inhibitor.